mebendazole has been researched along with Ovarian Neoplasms in 3 studies
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mebendazole was evaluated in cisplatin-resistant high grade serous stage 3C ovarian cancer patient derived xenograft (PDX) models: PDX-0003 (p53 null) and PDX-0030 (p53 positive), and on ovarian cancer cell lines: MES-OV (p53 R282W), ES2 (p53 S241F), A2780 (p53 wild type), SKOV3 parental (p53 null) and isogenic sublines, SKOV3 R273H p53 and SKOV3 R248W p53." | 1.62 | Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. ( Benbrook, DM; Bieniasz, M; Elayapillai, S; Gunderson, CC; Hunsucker, LA; Isingizwe, ZR; Kennedy, AL; Lightfoot, S; Pathuri, G; Ramraj, S; Wang, L; Zhao, YD, 2021) |
| "Ovarian cancer is the third most common cancer and the second most common cause of gynecologic cancer death in women." | 1.62 | Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. ( Chen, C; Haydon, RC; He, F; He, TC; Huang, L; Liu, Q; Luu, HH; Ni, N; Reid, RR; Shen, L; Shi, D; Tang, L; Wagstaff, W; Wang, H; Zhang, J; Zhao, L, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Elayapillai, S | 1 |
| Ramraj, S | 1 |
| Benbrook, DM | 1 |
| Bieniasz, M | 1 |
| Wang, L | 1 |
| Pathuri, G | 1 |
| Isingizwe, ZR | 1 |
| Kennedy, AL | 1 |
| Zhao, YD | 1 |
| Lightfoot, S | 1 |
| Hunsucker, LA | 1 |
| Gunderson, CC | 1 |
| Huang, L | 1 |
| Zhao, L | 1 |
| Zhang, J | 1 |
| He, F | 1 |
| Wang, H | 1 |
| Liu, Q | 1 |
| Shi, D | 1 |
| Ni, N | 1 |
| Wagstaff, W | 1 |
| Chen, C | 1 |
| Reid, RR | 1 |
| Haydon, RC | 1 |
| Luu, HH | 1 |
| Shen, L | 1 |
| He, TC | 1 |
| Tang, L | 1 |
| Mousa, AM | 1 |
| Mehrez, MG | 1 |
| Muhtaseb, SA | 1 |
| Al-Mudalal, DS | 1 |
| Kamel, SM | 1 |
3 other studies available for mebendazole and Ovarian Neoplasms
| Article | Year |
|---|---|
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Repositioning; Drug | 2021 |
Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
Topics: Animals; Antinematodal Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell | 2021 |
Disseminated pelvic hydatidosis presenting as ovarian carcinomatosis: successful post-operative treatment with mebendazole.
Topics: Diagnosis, Differential; Echinococcosis; Female; Humans; Mebendazole; Ovarian Neoplasms | 1987 |